|This message contains images. If you don't see images, click here to view.|
here to advertise in this news brief.
AST Corporate Affiliates
The AST thanks the following organizations for their participation in the 2014 Corporate Affiliates Program:
Astellas Pharma US, Inc.
The AST Corporate Affiliates Program provides an exciting opportunity for companies to support the work of the AST and receive tangible benefits throughout the year.
Genentech, A Member of the Roche Group
Novartis Pharmaceuticals Corporation
Roche Diagnostics Corporation
Benefits of participation include increased visibility, enhanced engagement opportunities, access to new marketing tools, and up-to-date communication about the latest research and advocacy efforts in the field of transplantation. For additional information, please visit us at www.myAST.org/CAP.
Now accepting abstracts!
AST + ESOT Joint Meeting
Personalized Transplantation: From New Diagnostics to New Therapeutics
Submit your clinical, translational and basic abstracts on Novel Immune Monitoring and/or Diagnostics and Immunosuppression Strategies.
Submission Deadline: Sunday, June 29
Long-term graft and patient survival are the key issues in transplantation. Outcomes are affected by individual immune risk and co-morbidities, as well as gender and race. The time is now to focus on improving outcomes through personalized medicine and finding the optimal combination of immunosuppressive drugs in the right dose for each patient.
'A Discussion of Risk in Living Kidney Donors' and other online education activities
On Tuesday, April 22, at 2 p.m. ET, join a transplant nephrologist, transplant surgeon, and epidemiologist as they discuss the risk of ESRD in living kidney donors, focusing on two recent publications in JAMA and Kidney International. Registration is open now. The presenters will provide:
AST also offers popular webinars on demand at http://www.myast.org/T3 and at www.myAST.org/content/fellows-live-webinar-series, including understanding the new UNOS/OPTN kidney allocation policy!
- A brief overview of risks of living kidney donation known to date
- Discussion of the study design, methods and statistics in the manuscripts
- Implications of the manuscripts on living kidney donation and how to discuss risk with living donors in the context of this new information
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
The University Of Utah Department Of Surgery is seeking applications for a faculty member to join the multi-organ transplant team at the assistant professor level. This is an opportunity to join an expanding program and a cohesive group of transplant surgeons focused on excellence. The candidate should be board certified in general surgery and have completed an ASTS approved transplantation surgery fellowship. Apply here
OTTR is pleased to be recognized for Excellence in Software by USIEC and for receiving CIBMTR Certification. Please contact us at ottr.com to see how we can help you.
Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant
Clinical Transplantation (login required)
Chronic kidney disease is a common complication of calcineurin inhibitors in solid organ transplantation. Previous data suggest that the use of everolimus as an immunosuppressant drug leads to improvement in renal function. The aim of our study was to establish the effect of everolimus in combination with lower doses of CNIs on renal function among lung transplant recipients. Data regarding renal function and pulmonary function were collected from 41 lung transplanted patients in whom treatment was converted to a combination of everolimus with lower doses of CNIs.
Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure
Transplantation (login required)
When kidney transplants fail, transplant medications are discontinued to reduce immunosuppression-related risks. However, retransplant candidates are at risk for allosensitization which prolonging immunosuppression may minimize. It has been hypothesized that for these patients, a prolonged immunosuppression withdrawal after graft failure preserves nonsensitization status better than early immunosuppression withdrawal.
NASH with liver transplantation related to early CVD mortality
Patients who underwent perioperative liver transplantation and had nonalcoholic steatohepatitis were at increased risk for early cardiovascular disease-related mortality, according to research presented at the International Liver Congress.“We have demonstrated that [nonalcoholic steatohepatitis] NASH patients have an increased risk of cardiovascular disease-related mortality within 30 days following liver transplant compared to other indications for transplant, even after controlling for pre-existing cardiac risk factors,” Dr. Lisa B. VanWagner, MS, clinical fellow in the division of gastroenterology and hepatology, Northwestern University Feinberg School of Medicine.
Study: Hepatitis C disease severity in living versus deceased donor liver transplant recipients
Donor factors influence hepatitis C virus disease severity in liver transplant recipients. Living donors, because they are typically young and have short cold ischemic times, may be advantageous for HCV-infected patients. Among HCV-infected patients in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study surviving more than 90 days and followed for a median 4.7 years, advanced fibrosis and graft loss were determined.
Missed last week's issue? See which articles your colleagues read most.
Public attitudes and beliefs about living kidney donation
Transplantation (login required)
With the rising prevalence of end-stage kidney disease worldwide, the proportion of the general community who might subsequently be called upon to consider living related kidney donation is also increasing. Knowledge about the attitudes and beliefs among the general public about living kidney donation is limited. We aimed to describe public perspectives on living kidney donation.
Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation
Liver Transplantation (login required)
Muscle depletion or sarcopenia is associated with increased mortality in patients with cirrhosis; how it affects mortality after liver transplantation requires further study. In this study, authors aimed to establish whether sarcopenia predicts increased morbidity or mortality after liver transplantation.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063